Testing for new oral anticoagulants with LA-resistant Russells viper venom reagents. An in vitro study.

Suppr

超能文献

作者信息

Exner Thomas, Ellwood Lisa, Rubie Jenny, Barancewicz Aileen

出版信息

Thromb Haemost. 2013 Apr;109(4):762-5. doi: 10.1160/TH12-11-0842. Epub 2013 Jan 31.

DOI:10.1160/TH12-11-0842

PMID:23364321

Abstract

摘要

相似文献

Testing for new oral anticoagulants with LA-resistant Russells viper venom reagents. An in vitro study.

Thromb Haemost. 2013 Apr;109(4):762-5. doi: 10.1160/TH12-11-0842. Epub 2013 Jan 31.

Facts and artefacts of coagulation assays for factor Xa inhibitors.凝血因子Xa抑制剂凝血检测的事实与假象

Thromb Haemost. 2010 Apr;103(4):686-8. doi: 10.1160/TH10-01-0080. Epub 2010 Feb 19.

Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.评估用于检测利伐沙班（一种口服、直接的 Xa 因子抑制剂）的实验室检测方法。

Thromb Haemost. 2010 Apr;103(4):815-25. doi: 10.1160/TH09-03-0176. Epub 2010 Feb 2.

Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays.利伐沙班对一期法和发色底物法检测因子VIII:C的干扰

Thromb Haemost. 2011 Nov;106(5):990-2. doi: 10.1160/TH11-04-0277. Epub 2011 Sep 8.

Laboratory identification of lupus anticoagulants using the combination of activated partial thromboplastin time and Russell's viper venom at two phospholipid concentrations.在两种磷脂浓度下，使用活化部分凝血活酶时间和蝰蛇毒的组合对狼疮抗凝物进行实验室鉴定。

J Med Assoc Thai. 2003 Jun;86 Suppl 2:S451-8.

Presence of direct thrombin inhibitors can affect the results and interpretation of lupus anticoagulant testing.

Am J Clin Pathol. 2005 Oct;124(4):586-93. doi: 10.1309/7RYUN5DRK4WCH3PM.

The Russell viper venom time (RVVT) test for investigation of lupus anticoagulant (LA).用于狼疮抗凝物（LA）检测的 Russell 蝰蛇 venom 时间（RVVT）试验。

Am J Hematol. 2019 Nov;94(11):1290-1296. doi: 10.1002/ajh.25606. Epub 2019 Aug 29.

Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.利伐沙班（一种口服活性Xa因子抑制剂）在大鼠颈动脉血栓形成电解损伤模型中的动脉抗血栓活性。

Blood Coagul Fibrinolysis. 2011 Dec;22(8):720-6. doi: 10.1097/MBC.0b013e32834cb30e.

Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.实验室检测评估阿哌沙班血药浓度：三种抗 Xa 检测方法的适用性。一项多中心法国 GEHT 研究。

Thromb Haemost. 2014 Feb;111(2):240-8. doi: 10.1160/TH13-06-0470. Epub 2013 Oct 31.

The Textarin/Ecarin ratio: a confirmatory test for lupus anticoagulants.替他加林/蛇毒凝血酶比率：狼疮抗凝物的确证试验。

Thromb Haemost. 1993 Dec 20;70(6):925-31.

引用本文的文献

Clot time ratio (CTR) and relation to treatment outcome in patients with atrial fibrillation treated with Rivaroxaban.利伐沙班治疗的房颤患者的凝血时间比（CTR）及其与治疗结果的关系。

Thromb J. 2024 Mar 1;22(1):24. doi: 10.1186/s12959-024-00591-x.

Comparison of different laboratory tests in the evaluation of hemorrhagic risk of patients using rivaroxaban in the critical care setting: diagnostic accuracy study.危重症环境下使用利伐沙班患者出血风险评估中不同实验室检查的比较：诊断准确性研究

Thromb J. 2017 Aug 15;15:21. doi: 10.1186/s12959-017-0140-6. eCollection 2017.

Perioperative management of patients on direct oral anticoagulants.接受直接口服抗凝剂治疗患者的围手术期管理。

Thromb J. 2017 May 15;15:14. doi: 10.1186/s12959-017-0137-1. eCollection 2017.

Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism.依度沙班：用于治疗心房颤动和静脉血栓栓塞的药理学与临床数据综合综述

Cardiol Ther. 2016 Jun;5(1):1-18. doi: 10.1007/s40119-016-0058-2. Epub 2016 Mar 2.

Monitoring anticoagulant therapy with new oral agents.使用新型口服制剂监测抗凝治疗。

World J Methodol. 2015 Dec 26;5(4):212-5. doi: 10.5662/wjm.v5.i4.212.

Supporting the use of a coagulometric method for rivaroxaban control: a hypothesis-generating study to define the safety cut-offs.支持使用凝血测定法监测利伐沙班：一项生成假设的研究以确定安全临界值。

Thromb J. 2015 Aug 6;13:26. doi: 10.1186/s12959-015-0058-9. eCollection 2015.

Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations.非维生素K拮抗剂口服抗凝剂：血浆药物浓度的准确测量

Biomed Res Int. 2015;2015:345138. doi: 10.1155/2015/345138. Epub 2015 May 19.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验